76 related articles for article (PubMed ID: 9467283)
41. [Ezetimib plus statin combination. A strong duo].
MMW Fortschr Med; 2002 Nov; 144(48):53. PubMed ID: 12532547
[No Abstract] [Full Text] [Related]
42. [Cost effectiveness is based on a hypothesis].
Lindberg M
Lakartidningen; 1998 Jan; 95(5):368. PubMed ID: 9492480
[No Abstract] [Full Text] [Related]
43. [New lower cholesterol levels: How much does it cost? Who is to pay?].
Lindberg M
Ugeskr Laeger; 2004 Nov; 166(49):4493-4; author reply 4494. PubMed ID: 15626108
[No Abstract] [Full Text] [Related]
44. [Even at LDL cholesterol 100mg/dl. "Every coronary disease patient has to receive a statin"].
MMW Fortschr Med; 2003 Dec; 145(49):57. PubMed ID: 14963997
[No Abstract] [Full Text] [Related]
45. [Cost-benefit analysis of anticholesteremic treatment].
Tidsskr Nor Laegeforen; 1989 Aug; 109(22):2171-3. PubMed ID: 2505403
[No Abstract] [Full Text] [Related]
46. Simvastatin: building on success.
Gaw A
Hosp Med; 2001 Jan; 62(1):29-32. PubMed ID: 11211458
[TBL] [Abstract][Full Text] [Related]
47. New cholesterol drugs are overpriced, independent analysis finds.
McCarthy M
BMJ; 2015 Sep; 351():h4864. PubMed ID: 26359445
[No Abstract] [Full Text] [Related]
48. Use of statins. Glasgow has already produced strategy for treatment.
McMurray J; McGuire A; Raikou M; Morrison C
BMJ; 1997 Dec; 315(7122):1617-8. PubMed ID: 9437292
[No Abstract] [Full Text] [Related]
49. [Statins without prescription?].
Reikvam A
Tidsskr Nor Laegeforen; 2005 Feb; 125(3):275. PubMed ID: 15702144
[No Abstract] [Full Text] [Related]
50. How much do we pay for a benefit? A descriptive cost analysis of the use of statins. The need for a national cost-effectiveness analysis.
Vieira JL; Portal VL; Moriguchi EH
Arq Bras Cardiol; 2001 May; 76(5):409-18. PubMed ID: 11359190
[No Abstract] [Full Text] [Related]
51. The primacy of clinical effectiveness for cost effectiveness analysis.
Casserly IP; Topol EJ
Heart; 2003 Mar; 89(3):249-50. PubMed ID: 12591818
[No Abstract] [Full Text] [Related]
52. [Misleading information about statins].
Røiri P
Tidsskr Nor Laegeforen; 2002 Sep; 122(21):2141. PubMed ID: 12555655
[No Abstract] [Full Text] [Related]
53. [The 4S study is analysed. Cholesterol reduction is cost-efficient].
Jönsson B; Johannesson M; Olsson AG
Lakartidningen; 1997 Dec; 94(51-52):4931-4. PubMed ID: 9454018
[No Abstract] [Full Text] [Related]
54. [SBU should investigate what is an evidence-based and cost-effective use of statins].
Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
Lakartidningen; 2009 Aug 5-18; 106(32-33):1992-4. PubMed ID: 19764381
[No Abstract] [Full Text] [Related]
55. [The new debate on cholesterol: is the lowest level the best?].
Olsson AG
Lakartidningen; 1999 Feb; 96(6):648-52. PubMed ID: 10087815
[No Abstract] [Full Text] [Related]
56. [Also elderly patients with hyperlipidemia and coronary disease need lipid lowering agents].
Hellénius ML
Lakartidningen; 2001 Sep; 98(39):4188-90. PubMed ID: 11680152
[No Abstract] [Full Text] [Related]
57. [Be careful about pseudo-information on cost-effectiveness].
Lindberg M
Lakartidningen; 1998 Jan; 95(3):144. PubMed ID: 9467283
[No Abstract] [Full Text] [Related]
58. [Simvastatin 40 mg as secondary prophylaxis: Effective, tolerable and cost-efficient!].
Hernborg A; Hjemdahl P; Håkansson J
Lakartidningen; 2006 Mar 15-21; 103(11):858, 861; discussion 861-2. PubMed ID: 16613120
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
